ImmunityBio (IBRX) Operating Income (2014 - 2026)
ImmunityBio's (IBRX) quarterly Operating Income came in at -$69.8 million in Q1 2026, down 8.32% year-on-year from -$76.1 million in Q1 2025, and down 7.9% on a QoQ basis from -$64.7 million in Q4 2025.
ImmunityBio (IBRX) Operating Income (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Operating Income data on file, last reported at -$69.8 million in Q1 2026.
- On a quarterly basis, Operating Income fell 8.32% year-over-year to -$69.8 million in Q1 2026; TTM through Mar 2026 was -$261.4 million, a 16.6% increase from a year earlier, with the FY2025 full-year figure at -$256.0 million, up 25.61% from the prior year.
- Operating Income for Q1 2026 stood at -$69.8 million, down from -$64.7 million in the prior quarter.
- Over the last five years, Operating Income for IBRX reached as high as -$55.6 million in Q3 2025 and fell as low as -$111.6 million in Q1 2023.
- Historically, Operating Income has averaged -$81.4 million across 5 years, with a median of -$80.3 million in 2024.
- Across the five-year window, Operating Income dropped 16.66% in 2024 and jumped 32.32% in 2025, its largest moves.
- Year by year, Operating Income stood at -$84.9 million in 2022, then declined by 0.58% to -$85.4 million in 2023, then rose by 18.72% to -$69.4 million in 2024, then gained by 6.8% to -$64.7 million in 2025, then fell by 7.9% to -$69.8 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$69.8 million in Q1 2026, -$64.7 million in Q4 2025, and -$55.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | ImmunityBio | 7.35 Bn | 6.97 Bn | 43.97 Mn | -69.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.79 Mn |
| Dec 31, 2025 | -64.68 Mn |
| Sep 30, 2025 | -55.63 Mn |
| Jun 30, 2025 | -71.29 Mn |
| Mar 31, 2025 | -64.43 Mn |
| Dec 31, 2024 | -69.40 Mn |
| Sep 30, 2024 | -80.25 Mn |
| Jun 30, 2024 | -99.33 Mn |
| Mar 31, 2024 | -95.20 Mn |
| Dec 31, 2023 | -85.39 Mn |
| Sep 30, 2023 | -80.14 Mn |
| Jun 30, 2023 | -85.15 Mn |
| Mar 31, 2023 | -111.58 Mn |
| Dec 31, 2022 | -84.90 Mn |
| Sep 30, 2022 | -90.80 Mn |
| Jun 30, 2022 | -79.62 Mn |
| Mar 31, 2022 | -95.97 Mn |
| Dec 31, 2021 | -79.27 Mn |
| Sep 30, 2021 | -78.84 Mn |
| Jun 30, 2021 | -85.91 Mn |